Sign in
Taking peoplePhase 2

A Superiority Study of Model-Guided Optimized Dosing Versus Empirical Dosing of Piperacillin/Tazobactam in the Treatment of Community-Acquired Pneumonia in Elderly Patients

Key facts

Who runs it
Shandong University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
118 people, planned
Started
17 Jul 2026
Expected to end
31 May 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®)
Record updated
18 November 2026

Who can take part

Age
65 years to 110 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (15)Hide the full registry criteria

Who can take part

  • Age ≥ 65 years
  • Clinically diagnosed or highly suspected community-acquired pneumonia (CAP). CAP clinical diagnostic criteria: All three of the following must be met:; Onset in the community setting; At least one of the following clinical manifestations:; New-onset cough, sputum production, or worsening of pre-existing respiratory symptoms, with or without purulent sputum, chest pain, dyspnea, or hemoptysis; Fever; Signs of pulmonary consolidation and/or moist rales; Peripheral white blood cell count > 10×10⁹/L or < 4×10⁹/L, with or without left shift; Chest imaging showing new patchy infiltrates, lobar/segmental consolidation, ground-glass opacities, or interstitial changes, with or without pleural effusion; For patients aged ≥ 65 years with a body temperature < 38°C, the presence of clear clinical signs of pneumonia and abnormal chest X-ray findings will also be considered meeting the inclusion criteria
  • At least one of the following risk factors for drug-resistant pathogens:; Comorbidities such as chronic cardiopulmonary disease, diabetes mellitus, renal failure, etc.; Use of broad-spectrum antibiotics within the past 3 months; History of repeated hospitalizations or residence in a long-term care facility
  • Patients are required to initiate intravenous empiric antimicrobial therapy, and piperacillin-tazobactam is considered appropriate empiric treatment
  • Expected length of hospital stay ≥ 72 hours
  • Signed informed consent form

Who cannot take part

  • Concurrent use of broad-spectrum antibiotics with similar antibacterial spectra, including cefoperazone-sulbactam, imipenem-cilastatin, meropenem, biapenem and others
  • Patients with severe allergy to β-lactams and history of severe adverse reactions
  • End-stage diseases with expected survival time shorter than the treatment course, such as advanced malignant tumors and end-stage organ failure
  • Any other conditions deemed ineligible for enrollment by investigators; Post-randomization exclusion criteria:
  • Isolated fungal infection
  • Isolated viral infection
  • Severe renal insufficiency with creatinine clearance <40 mL/min, or patients receiving continuous renal replacement therapy (CRRT)
  • Highly suspected or confirmed fungal pneumonia or viral pneumonia
  • Patients with confirmed pathogenic bacteria resistant to piperacillin-tazobactam (PIP/TAZO) during the study

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • PD target attainment rate or pneumonia or elderly

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study tests a new way to give an antibiotic to older adults with pneumonia. Pneumonia is a lung infection.

Read full original descriptionShow less

Piperacillin-tazobactam is an antibiotic. Doctors often use it to treat pneumonia in older adults. Right now, doctors usually give this drug every 8 hours. They let it drip into the vein over 3 hours.

But early research suggests a different schedule may work better. This study will test giving the drug every 6 hours. The drip will last 4 hours. Researchers think this may help the drug fight germs better.

The study will compare the usual schedule with the new schedule. Participants will join one of two groups. One group will get the usual schedule. The other group will get the new schedule.

Researchers will check how well the drug works. They will also watch for side effects. They want to find the safest and most helpful way to give this drug.

Adults aged 65 and older with community-acquired pneumonia can join. Community-acquired pneumonia is a lung infection that starts outside of a hospital.

The 2 groups in the trial

  • guideline-based conventional dosingExisting treatment, for comparison

    Treatment: Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®)

  • Model-guided optimized dosingTreatment being tested

    Treatment: Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®)

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Superiority Study Comparing Model-Guided Optimized Dosing With Empirical Dosing of Piperacillin/Tazobactam in Elderly Patients With Community-Acquired Pneumonia
Criteria questions
Built from NCT07945275, who can take part
Record updated
18 November 2026